Cargando…

Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma

Background: Due to resistance to conventional therapy, a blood–brain barrier that results in poor drug delivery, and a high potential for metastasis, glioblastoma (GBM) presents a great medical challenge. Since the repertoire of the possible therapies is very limited, novel therapeutic strategies re...

Descripción completa

Detalles Bibliográficos
Autores principales: Sowińska, Marta, Szeliga, Monika, Morawiak, Maja, Zabłocka, Barbara, Urbanczyk-Lipkowska, Zofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406037/
https://www.ncbi.nlm.nih.gov/pubmed/36009010
http://dx.doi.org/10.3390/biom12081116
_version_ 1784774025634906112
author Sowińska, Marta
Szeliga, Monika
Morawiak, Maja
Zabłocka, Barbara
Urbanczyk-Lipkowska, Zofia
author_facet Sowińska, Marta
Szeliga, Monika
Morawiak, Maja
Zabłocka, Barbara
Urbanczyk-Lipkowska, Zofia
author_sort Sowińska, Marta
collection PubMed
description Background: Due to resistance to conventional therapy, a blood–brain barrier that results in poor drug delivery, and a high potential for metastasis, glioblastoma (GBM) presents a great medical challenge. Since the repertoire of the possible therapies is very limited, novel therapeutic strategies require new drugs as well as new approaches. The multiple roles played by L-tryptophan (Trp) in tumorigenesis of GBM and the previously found antiproliferative properties of Trp-bearing dendrimers against this malignancy prompted us to design novel polyfunctional peptide-based dendrimers covalently attached to N(1)-alkyl tryptophan (Trp) residues. Their antiproliferative properties against GBM and normal human astrocytes (NHA) and their antioxidant potential were tested. Methods: Two groups of amphiphilic peptide dendrimers terminated with N(1)-butyl and N(1)-aminopentane tryptophan were designed. The influence of dendrimers on viability of NHA and human GBM cell lines, displaying different genetic backgrounds and tumorigenic potentials, was determined by the MTT test. The influence of compounds on the clonogenic potential of GBM cells was assessed by colony-formation assay. Dendrimers were tested for radical scavenging potency as well as redox capability (DPPH, ABTS, and FRAP models). Results: Several peptide dendrimers functionalized with N(1)-alkyl-tryptophan at 5 µM concentration exhibited high selectivity towards GBM cells retaining 85–95% viable NHA cells while killing cancer cells. In both the MTT and colony-formation assays, compounds 21 (functionalized with N(1)-butyl-Trp and (+)8 charged) and 25 (functionalized with N(1)-aminopentane-Trp and (+)12 charged) showed the most promise for their development into anticancer drugs. According to ABTS, DPPH, and FRAP antioxidant tests, dendrimers functionalized with N(1)-alkylated Trp expressed higher ROS-scavenging capacity (ABTS and DPPH) than those with unsubstituted Trp. Conclusions: Peptide dendrimers functionalized with N(1)-alkyl-tryptophan showed varying toxicity to NHA, while all were toxic to GBM cells. Based on their activity towards inhibition of GBM viability and relatively mild effect on NHA cells the most advantageous were derivatives 21 and 25 with the respective di-dodecyl and dodecyl residue located at the C-terminus. As expected, peptide dendrimers functionalized with N(1)-alkyl-tryptophan expressed higher scavenging potency against ROS than dendrimers with unsubstituted tryptophan.
format Online
Article
Text
id pubmed-9406037
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94060372022-08-26 Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma Sowińska, Marta Szeliga, Monika Morawiak, Maja Zabłocka, Barbara Urbanczyk-Lipkowska, Zofia Biomolecules Article Background: Due to resistance to conventional therapy, a blood–brain barrier that results in poor drug delivery, and a high potential for metastasis, glioblastoma (GBM) presents a great medical challenge. Since the repertoire of the possible therapies is very limited, novel therapeutic strategies require new drugs as well as new approaches. The multiple roles played by L-tryptophan (Trp) in tumorigenesis of GBM and the previously found antiproliferative properties of Trp-bearing dendrimers against this malignancy prompted us to design novel polyfunctional peptide-based dendrimers covalently attached to N(1)-alkyl tryptophan (Trp) residues. Their antiproliferative properties against GBM and normal human astrocytes (NHA) and their antioxidant potential were tested. Methods: Two groups of amphiphilic peptide dendrimers terminated with N(1)-butyl and N(1)-aminopentane tryptophan were designed. The influence of dendrimers on viability of NHA and human GBM cell lines, displaying different genetic backgrounds and tumorigenic potentials, was determined by the MTT test. The influence of compounds on the clonogenic potential of GBM cells was assessed by colony-formation assay. Dendrimers were tested for radical scavenging potency as well as redox capability (DPPH, ABTS, and FRAP models). Results: Several peptide dendrimers functionalized with N(1)-alkyl-tryptophan at 5 µM concentration exhibited high selectivity towards GBM cells retaining 85–95% viable NHA cells while killing cancer cells. In both the MTT and colony-formation assays, compounds 21 (functionalized with N(1)-butyl-Trp and (+)8 charged) and 25 (functionalized with N(1)-aminopentane-Trp and (+)12 charged) showed the most promise for their development into anticancer drugs. According to ABTS, DPPH, and FRAP antioxidant tests, dendrimers functionalized with N(1)-alkylated Trp expressed higher ROS-scavenging capacity (ABTS and DPPH) than those with unsubstituted Trp. Conclusions: Peptide dendrimers functionalized with N(1)-alkyl-tryptophan showed varying toxicity to NHA, while all were toxic to GBM cells. Based on their activity towards inhibition of GBM viability and relatively mild effect on NHA cells the most advantageous were derivatives 21 and 25 with the respective di-dodecyl and dodecyl residue located at the C-terminus. As expected, peptide dendrimers functionalized with N(1)-alkyl-tryptophan expressed higher scavenging potency against ROS than dendrimers with unsubstituted tryptophan. MDPI 2022-08-13 /pmc/articles/PMC9406037/ /pubmed/36009010 http://dx.doi.org/10.3390/biom12081116 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sowińska, Marta
Szeliga, Monika
Morawiak, Maja
Zabłocka, Barbara
Urbanczyk-Lipkowska, Zofia
Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma
title Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma
title_full Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma
title_fullStr Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma
title_full_unstemmed Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma
title_short Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma
title_sort design, synthesis and activity of new n(1)-alkyl tryptophan functionalized dendrimeric peptides against glioblastoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406037/
https://www.ncbi.nlm.nih.gov/pubmed/36009010
http://dx.doi.org/10.3390/biom12081116
work_keys_str_mv AT sowinskamarta designsynthesisandactivityofnewn1alkyltryptophanfunctionalizeddendrimericpeptidesagainstglioblastoma
AT szeligamonika designsynthesisandactivityofnewn1alkyltryptophanfunctionalizeddendrimericpeptidesagainstglioblastoma
AT morawiakmaja designsynthesisandactivityofnewn1alkyltryptophanfunctionalizeddendrimericpeptidesagainstglioblastoma
AT zabłockabarbara designsynthesisandactivityofnewn1alkyltryptophanfunctionalizeddendrimericpeptidesagainstglioblastoma
AT urbanczyklipkowskazofia designsynthesisandactivityofnewn1alkyltryptophanfunctionalizeddendrimericpeptidesagainstglioblastoma